Jacobs Levy Equity Management, Inc Coherus Bio Sciences, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 252,330 shares of CHRS stock, worth $194,294. This represents 0.0% of its overall portfolio holdings.
Number of Shares
252,330
Previous 1,001,057
74.79%
Holding current value
$194,294
Previous $1.73 Million
84.86%
% of portfolio
0.0%
Previous 0.01%
Shares
24 transactions
Others Institutions Holding CHRS
# of Institutions
135Shares Held
78.3MCall Options Held
40.7KPut Options Held
50.1K-
Black Rock Inc. New York, NY11.8MShares$9.05 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$8.71 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$8.01 Million0.3% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$2.34 Million0.18% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$2.2 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $59.8M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...